ORG-12962

ORG-12962 is a serotonin receptor agonist that was developed by Organon International for the treatment of various medical conditions. It has a high affinity for the 5-HT2C receptor, and is believed to be a potent and selective 5-HT2C agonist.

History

ORG-12962 was first synthesized by Organon International, a pharmaceutical company based in the Netherlands. The compound was developed as part of Organon's research into serotonin receptor agonists, which are drugs that can stimulate the activity of the serotonin system in the brain.

Pharmacology

ORG-12962 is a potent and selective agonist for the 5-HT2C receptor, one of the many subtypes of serotonin receptors in the brain. This means that it can bind to this receptor and activate it, leading to an increase in the activity of the serotonin system.

The 5-HT2C receptor is involved in a variety of physiological processes, including mood regulation, appetite control, and the release of various hormones. By activating this receptor, ORG-12962 could potentially be used to treat a variety of medical conditions, including depression, anxiety disorders, and obesity.

Clinical Trials

As of now, there is limited information available about the clinical trials of ORG-12962. Further research and clinical trials are needed to fully understand the potential therapeutic uses and side effects of this compound.

See Also

• Serotonin receptor agonist
• 5-HT2C receptor
• Organon International

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia